Surgery Partners (SGRY) Q1 2025: Orthopedic Joint Cases Surge 22%, Fueling High-Acuity Growth

2025-05-12 | By EarningsIQ Research

Surgery Partners’ Q1 2025 results highlight a decisive pivot toward higher-acuity procedures, with orthopedic joint surgeries up 22% year-over-year, even as lower-reimbursing GI volumes weighed on average rates. The company’s multi-pronged growth algorithm—balancing organic volume, margin initiatives, and disciplined M&A—remains intact, with robust physician recruiting and a de novo pipeline underpinning future expansion. Management reaffirmed full-year guidance and pointed to strong cash generation and limited tariff or payer risk, signaling confidence in sustained outperformance relative to industry peers.

Summary

• Orthopedic Expansion Accelerates: Total joint surgeries grew 22%, reinforcing SGRY’s higher-acuity strategy.
• Margin Levers Offset Mix Pressure: Operating system improvements and integration gains support annual margin expansion despite near-term rate headwinds.
• De Novo and M&A Pipeline Robust: Strong physician recruiting, 10 de novos in development, and $55M deployed in acquisitions set up multi-year growth.

Performance Analysis

Surgery Partners delivered 8% revenue growth and nearly 7% adjusted EBITDA growth in Q1 2025, with case volume up 6.5% and same-facility revenue growth of 5.2%. This performance was driven by broad-based volume gains across all core specialties, most notably in orthopedics and GI (gastrointestinal), which together make up a significant share of the surgical mix. The company performed over 160,000 surgical cases, up from 153,000 a year ago, and orthopedic cases rose 3.4%—with total joint procedures up a striking 22%.

Revenue per case was pressured by a higher proportion of lower-acuity GI procedures and a strong comp from the prior year, resulting in a slight rate decline. Despite this, the company’s margin held at 13.4%, as operating efficiencies, procurement, and integration benefits from recent acquisitions offset mix-driven headwinds. Cash flow was seasonally lower due to timing of partner distributions, but underlying cash conversion improved, with days sales outstanding down two days sequentially.

• Case Mix Shift: Robust GI growth raised overall case counts but diluted average revenue per case.
• Orthopedic Outperformance: Total joint procedures now represent a growing share of high-value cases, supporting the company’s acuity mix thesis.
• Cash Flow Dynamics: Partner distributions doubled in Q1 due to timing, but normalized cash generation is expected to strengthen through the year.

Overall, SGRY’s financials reflect a business balancing high-volume, lower-rate growth with strategic investment in higher-acuity specialties and disciplined capital deployment.

Executive Commentary

Strategic Positioning

1. High-Acuity Orthopedic Growth

Surgery Partners’ strategic emphasis on orthopedics—particularly total joint procedures—positions the company to capture outsized value as payers and patients shift to lower-cost, high-quality ambulatory settings. With 80% of facilities equipped for higher-acuity orthopedics and nearly half performing total joint cases, SGRY is leveraging targeted physician recruitment and investments in robotics to deepen its competitive moat. The 22% growth in total joint procedures is a clear validation of this strategy and supports future margin expansion as the mix skews higher-acuity.

2. De Novo and M&A Pipeline

The company’s de novo (new facility) strategy is gaining traction, with 10 projects under construction and a pipeline heavily weighted to high-acuity specialties. De novos offer compelling economics, with lower entry costs and attractive returns relative to traditional acquisitions. Meanwhile, SGRY’s disciplined M&A approach—$55 million deployed at sub-8x EBITDA multiples in Q1—adds immediate earnings and integration-driven margin upside. This dual approach enables SGRY to scale efficiently and refresh its portfolio for long-term growth.

3. Margin Expansion via Operating System Improvements

Margin improvement remains a core pillar, with ongoing gains from supply chain optimization, revenue cycle standardization, and integration of acquired assets. The company’s multi-year journey to a unified revenue cycle management platform is already yielding improvements in cash conversion and denial rates, while supply chain partnerships (notably with Health Trust) provide contract transparency and insulation from near-term tariff risk. These operating system enhancements underpin management’s confidence in delivering annual margin expansion despite mix and rate pressures.

4. Physician Recruitment as a Growth Engine

Physician recruiting is both a volume and acuity lever, with 150 new doctors added in Q1—skewing toward higher-revenue specialties. Year-two case and revenue contributions from prior cohorts have more than doubled, demonstrating a compounding effect that supports both organic and acquired growth. This recruiting engine is foundational to SGRY’s ability to drive same-facility growth above its long-term algorithm.

Key Considerations

This quarter’s results reinforce SGRY’s ability to execute on its three-pillar growth algorithm, while navigating mix headwinds and regulatory uncertainty.

Key Considerations:

• Case Mix Volatility: Higher GI volumes dilute average revenue per case, but are offset by accelerating orthopedic growth and increased total joint procedures.
• De Novo Ramp and M&A Integration: New facilities and recent acquisitions are on track, with integration synergies and margin expansion expected to compound through 2025.
• Cash Flow and Leverage Trajectory: Seasonal and timing impacts on cash flow are temporary, with leverage expected to decline as earnings grow and no need for external capital to fund expansion.
• Regulatory and Tariff Risk Mitigation: Minimal exposure to Medicaid/exchange reimbursement and strong supply chain contract protections limit near- and mid-term policy risk.
• Portfolio Refresh and Divestiture Discipline: Last year’s outsized divestitures are not expected to repeat, supporting stability in the core portfolio.

Risks

Key risks include ongoing case mix volatility—particularly if lower-acuity GI volumes further dilute rates—potential labor cost inflation in select specialties, and exposure to interest rate fluctuations as swap protections roll off. While management cites limited tariff and reimbursement risk, shifts in payer dynamics or regulatory action could still impact margins or volume over time. Integration of new facilities and physician cohorts also carries execution risk, especially as the company scales its de novo pipeline.

Forward Outlook

For Q2 2025, Surgery Partners guided to:

• Continued same-facility revenue growth at or above the high end of its 6% target range
• Margin expansion as higher-acuity volumes and integration synergies ramp

For full-year 2025, management reaffirmed guidance:

• Revenue of $3.3 to $3.45 billion
• Adjusted EBITDA of $555 to $565 million

Management highlighted several factors that bolster confidence:

• Strong physician recruiting and compounding case contributions from prior cohorts
• Robust de novo and M&A pipeline, with integration benefits expected to accelerate in H2

Takeaways

SGRY’s Q1 results reinforce the company’s positioning as a high-acuity, growth-focused platform that is executing across organic, M&A, and operational fronts.

• Orthopedic and De Novo Momentum: Accelerating total joint growth and a deep pipeline of new facilities set the stage for sustained outperformance in high-value procedures.
• Margin and Cash Conversion Discipline: Operating system improvements and integration gains are offsetting mix headwinds, with leverage on track to decline and no need for external capital.
• Future Watchpoint: Investors should monitor case mix evolution, integration of new assets, and the pace of margin expansion as the de novo and M&A strategies scale through 2025.

Conclusion

Surgery Partners enters the balance of 2025 with clear momentum in high-acuity specialties, disciplined capital deployment, and operating leverage from ongoing system improvements. The company’s reaffirmed guidance and robust pipeline suggest continued industry-leading growth, though execution on mix and integration will remain critical watchpoints for investors.

Industry Read-Through

SGRY’s performance highlights a broader ambulatory surgery center (ASC) sector trend: migration of high-acuity procedures out of hospitals and into specialized, efficient outpatient settings. The company’s ability to recruit physicians, ramp de novos, and integrate acquisitions at scale is a template for peers seeking to capture share in orthopedics, GI, and emerging cardio procedures. Supply chain risk management and payer alignment—cited as strengths—are increasingly critical as ASC operators face regulatory and reimbursement uncertainty. SGRY’s multi-pronged growth engine and margin discipline set a high bar for industry participants navigating similar mix and cost dynamics.

SGRY Healthcare Ambulatory Surgery Centers Orthopedics De Novo M&A Margin Expansion Physician Recruitment